$ISCO
International Stem Cell CORP

2020 Q2 Form 10-Q Financial Statement

#000156459020039693 Filed on August 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q2
Revenue $1.812M
YoY Change -21.93%
Cost Of Revenue $719.0K
YoY Change -16.1%
Gross Profit $1.093M
YoY Change -25.34%
Gross Profit Margin 60.32%
Selling, General & Admin $1.725M
YoY Change -19.28%
% of Gross Profit 157.82%
Research & Development $200.0K
YoY Change -25.37%
% of Gross Profit 18.3%
Depreciation & Amortization $65.00K
YoY Change -1.52%
% of Gross Profit 5.95%
Operating Expenses $1.925M
YoY Change -19.96%
Operating Profit -$832.0K
YoY Change -11.58%
Interest Expense -$254.0K
YoY Change -1370.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.086M
YoY Change 67.59%
Income Tax
% Of Pretax Income
Net Earnings -$1.086M
YoY Change 67.59%
Net Earnings / Revenue -59.93%
Basic Earnings Per Share
Diluted Earnings Per Share -$144.1K
COMMON SHARES
Basic Shares Outstanding 7.539M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.315M
YoY Change 119.17%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $379.0K
YoY Change -13.86%
Inventory $1.010M
Prepaid Expenses
Receivables $694.0K
Other Receivables $0.00
Total Short-Term Assets $3.398M
YoY Change 2.1%
LONG-TERM ASSETS
Property, Plant & Equipment $1.613M
YoY Change 131.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $427.0K
YoY Change -51.48%
Total Long-Term Assets $3.385M
YoY Change -35.07%
TOTAL ASSETS
Total Short-Term Assets $3.398M
Total Long-Term Assets $3.385M
Total Assets $6.783M
YoY Change -20.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $579.0K
YoY Change -20.79%
Accrued Expenses $830.0K
YoY Change 51.46%
Deferred Revenue
YoY Change
Short-Term Debt $2.422M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.081M
YoY Change -8.46%
LONG-TERM LIABILITIES
Long-Term Debt $654.0K
YoY Change
Other Long-Term Liabilities $1.353M
YoY Change 39.48%
Total Long-Term Liabilities $2.007M
YoY Change 106.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.081M
Total Long-Term Liabilities $2.007M
Total Liabilities $6.088M
YoY Change 12.08%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.605M
YoY Change
Total Liabilities & Shareholders Equity $6.783M
YoY Change -20.57%

Cashflow Statement

Concept 2020 Q2
OPERATING ACTIVITIES
Net Income -$1.086M
YoY Change 67.59%
Depreciation, Depletion And Amortization $65.00K
YoY Change -1.52%
Cash From Operating Activities -$18.00K
YoY Change -97.22%
INVESTING ACTIVITIES
Capital Expenditures -$29.00K
YoY Change -83.14%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$29.00K
YoY Change -83.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 654.0K
YoY Change -18.25%
NET CHANGE
Cash From Operating Activities -18.00K
Cash From Investing Activities -29.00K
Cash From Financing Activities 654.0K
Net Change In Cash 607.0K
YoY Change -3135.0%
FREE CASH FLOW
Cash From Operating Activities -$18.00K
Capital Expenditures -$29.00K
Free Cash Flow $11.00K
YoY Change -102.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2019Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
207000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4081000
CY2019Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
2370000
CY2020Q2 isco Paycheck Protection Program Loan
PaycheckProtectionProgramLoan
654000
CY2020Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
322000
CY2019Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2000
CY2019Q1 isco Adjustments Related To Error Correction In Equity
AdjustmentsRelatedToErrorCorrectionInEquity
-4300000
CY2019Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1049000
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Share Based Compensation
ShareBasedCompensation
742000
us-gaap Profit Loss
ProfitLoss
-1459000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
128000
isco Inventory Adjustment
InventoryAdjustment
7000
isco Inventory Adjustment
InventoryAdjustment
22000
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
52000
CY2020Q2 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1366000
CY2019Q4 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1604000
us-gaap Operating Lease Expense
OperatingLeaseExpense
132000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-821000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-231000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
172000
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-19000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-75000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-142000
isco Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-152000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
247000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
654000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
800000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
654000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
831000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
484000
us-gaap Interest Paid Net
InterestPaidNet
3000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
421000
isco Patent License Costs Included In Accrued Liabilities
PatentLicenseCostsIncludedInAccruedLiabilities
7000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1049000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
742000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
571000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three and six months ended June 30, 2020, the Company reclassified certain prior period amounts to conform to the current period presentation, as follows:</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying value and shares of the Company&#8217;s Series B, Series G, Series I-1 and Series I-2 non-redeemable convertible preferred stock were aggregated on the accompanying condensed consolidated balance sheets and statements of changes in redeemable convertible preferred stock and stockholders&#8217; deficit. Refer to Note 6 &#8211; Convertible Preferred Stock and Stockholders&#8217; Deficit for further discussion;</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash operating lease expense was reclassified from changes in operating assets and liabilities to adjustments to reconcile net loss to net cash provided by (used in) operating activities on the accompanying condensed consolidated statements of cash flows; and</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financed insurance premiums and payments on financed insurance premiums were reclassified from non-cash financing activities and cash flows from financing activities, respectively, to cash flows from operating activities on the accompanying condensed consolidated statements of cash flows.</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These reclassifications had no effect on previously reported net loss, stockholders&#8217; deficit or cash flows for the prior period.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying condensed consolidated financial statements. Significant estimates include patent life (remaining legal life versus remaining useful life), inventory carrying values, allowance for excess and obsolete inventories, allowance for sales returns and doubtful accounts, and transactions using the Black-Scholes option valuation model, for example, common stock options and common stock warrants, as well as the Monte-Carlo simulation method for certain common stock warrants. Actual results could differ from those estimates.</p>
isco Related Party Rent Expense
RelatedPartyRentExpense
84000
isco Related Party Rent Expense
RelatedPartyRentExpense
80000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Customer Concentrations</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the six months ended June 30, 2020 and 2019, for the biomedical market segment, one customer accounted for approximately 47% and 52%, respectively, of consolidated revenues. As of June 30, 2020 and December 31, 2019, the customer accounted for approximately 63% and 37%, respectively, of accounts receivable, net. No other single customer accounted for more than 10% of revenues for the periods then ended.</p>
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P15Y
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
isco Number Of Business Units
NumberOfBusinessUnits
2
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12000
isco Cash Refund As Percentage Of Qualified Research And Development Expenditures
CashRefundAsPercentageOfQualifiedResearchAndDevelopmentExpenditures
0.435
CY2008Q2 isco Advances From Nonaffiliated Collaboration
AdvancesFromNonaffiliatedCollaboration
250000
CY2008Q2 isco Specified Amount Of Revenue To Be Utilized First For Advances
SpecifiedAmountOfRevenueToBeUtilizedFirstForAdvances
250000
us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
The Company's revenue consists primarily of sales of products from its two revenue-generating operating segments, the biomedical products market and anti-aging cosmetic products market business segments. The biomedical market segment markets and sells primary human cell research products with two product categories, cells and media, which are sold both domestically within the United States and internationally. The anti-aging cosmetic market segment markets and sells a line of luxury skincare products sold through two sales channels: ecommerce and professional. The ecommerce channel sells direct to customers through online orders, while professional sales are to spas, salons and other skincare providers.
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
isco Product Return Guarantee Period
ProductReturnGuaranteePeriod
P30D
isco Allowance For Sales Return
AllowanceForSalesReturn
0
CY2019 isco Allowance For Sales Return
AllowanceForSalesReturn
0
CY2020Q2 isco Financial Assets Fair Value Disclosure
FinancialAssetsFairValueDisclosure
0
CY2020Q2 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2020Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2016Q1 isco Class Of Warrant Or Right Issued Exercisable For Shares Of Common Stock
ClassOfWarrantOrRightIssuedExercisableForSharesOfCommonStock
11159995
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.75
CY2016Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.75
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1000000
CY2019Q1 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
49000
isco Convertible Common Stock Conversion Price
ConvertibleCommonStockConversionPrice
1.75
CY2020Q2 isco Paycheck Protection Program Loan Interest Rate
PaycheckProtectionProgramLoanInterestRate
0.01
CY2020Q2 isco Paycheck Protection Program Loan Deferred Payment Period
PaycheckProtectionProgramLoanDeferredPaymentPeriod
P10M
CY2020Q2 isco Paycheck Protection Program Loan Forgiveness Period
PaycheckProtectionProgramLoanForgivenessPeriod
P168D
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2020Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
322000
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14701262
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15753261
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14821561
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15753261
CY2020Q2 us-gaap Change In Accounting Principle Accounting Standards Update Adopted
ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
true
CY2020Q2 us-gaap Change In Accounting Principle Accounting Standards Update Adoption Date
ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
2020-01-01
CY2020Q2 us-gaap Change In Accounting Principle Accounting Standards Update Immaterial Effect
ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
true
us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201813Member
CY2020Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
641000
CY2019Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
688000
CY2020Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
427000
CY2019Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
492000
CY2020Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1100000
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1219000
CY2020Q2 us-gaap Inventory Gross
InventoryGross
2168000
CY2019Q4 us-gaap Inventory Gross
InventoryGross
2399000
CY2020Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
802000
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
795000
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3432000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2825000
CY2020Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
43000
CY2019Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
37000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
83000
CY2020Q2 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
2323000
CY2019Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
2268000
CY2020Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1053000
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1008000
CY2020Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1270000
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1260000
CY2020Q2 isco Indefinite Life Logos And Trademarks
IndefiniteLifeLogosAndTrademarks
75000
CY2019Q4 isco Indefinite Life Logos And Trademarks
IndefiniteLifeLogosAndTrademarks
75000
CY2020Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1345000
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1335000
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
23000
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
28000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
45000
CY2020Q2 isco Cares Act Of2020 Aid Amount
CARESActOf2020AidAmount
654000
CY2020Q2 isco Paycheck Protection Program Loan Maturity Period
PaycheckProtectionProgramLoanMaturityPeriod
P2Y
CY2014Q4 isco Class Of Warrant Or Right Issued Exercisable For Shares Of Common Stock
ClassOfWarrantOrRightIssuedExercisableForSharesOfCommonStock
62047
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
324000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1077000
CY2019Q4 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
500000
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y2M12D
CY2020Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
19618122
CY2019Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
800000
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
500000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1354000
isco Number Of Operating Leases
NumberOfOperatingLeases
3
us-gaap Operating Lease Cost
OperatingLeaseCost
237000
us-gaap Operating Lease Cost
OperatingLeaseCost
253000
CY2020Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
0
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
255000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
518000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
394000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
255000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
233000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
240000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1895000
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
541000

Files In Submission

Name View Source Status
0001564590-20-039693-index-headers.html Edgar Link pending
0001564590-20-039693-index.html Edgar Link pending
0001564590-20-039693.txt Edgar Link pending
0001564590-20-039693-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gvnsuenqtshh000001.jpg Edgar Link pending
gvnsuenqtshh000002.jpg Edgar Link pending
isco-10q_20200630.htm Edgar Link pending
isco-20200630.xml Edgar Link completed
isco-20200630.xsd Edgar Link pending
isco-20200630_cal.xml Edgar Link unprocessable
isco-20200630_def.xml Edgar Link unprocessable
isco-20200630_lab.xml Edgar Link unprocessable
isco-20200630_pre.xml Edgar Link unprocessable
isco-ex101_49.htm Edgar Link pending
isco-ex102_225.htm Edgar Link pending
isco-ex311_6.htm Edgar Link pending
isco-ex312_8.htm Edgar Link pending
isco-ex321_10.htm Edgar Link pending
isco-ex322_7.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending